An impressive immunotherapy is showing great promise for endometrial cancer patients at Ohio State. While previously-existing treatments for endometrial (also known as uterine) cancer can be successful, they often result in serious side effects for the impacted women. &ldquo;We had limited options and they had significant toxicity,&rdquo; says David O&rsquo;Malley, MD, the director of the OSUCCC &ndash; James Division of Gynecologic Oncology. In search of a better option for their patients, O&rsquo;Malley and the university&rsquo;s Gynecologic Oncology Phase I Program launched a clinical trial using pembrolizumab (marketed as Keytruda), an immunotherapy already used to treat several types of cancer. Learn more about clinical trials at the OSUCCC &ndash; James. The innovative treatment targets cellular receptors used by cancer cells to shield themselves from patients&rsquo; immune systems. &ldquo;Removing the blockers allows immune systems to identify and attack the cancer cells,&rdquo; O&rsquo;Malley says. The treatment has already improved outcomes for many patients involved in the study, with some women experiencing complete responses. &ldquo;There were 79 patients in the trial &mdash; 48 percent responded markedly, and for 14 percent, their cancers were completely gone,&rdquo; O&rsquo;Malley says. Learn more about endometrial cancer, including risks, symptoms and treatment options at Ohio State.